Relief Therapeutics has completed the study “Vasoactive Intestinal Peptide (VIP) for the Treatment of Drug-Induced Pneumonitis”
Relief Therapeutics Holding SA , a biopharmaceutical company aiming to provide patients with therapeutic relief from serious diseases with high unmet need, announced today that the Swiss Patent Office IPI expects to complete the patent application procedure by January 24, 2022 and to issue the patent entitled “Vasoactive Intestinal Peptide (VIP) for the Treatment of Drug-Induced Pneumonitis,” as applied for by Relief’s subsidiary, Aventis At the earliest, one month after the patent examination procedure is completed, the patent will be formally issued.
“The pending grant of this Swiss patent for the inhaled version of RLF-100™ (aviptadil) represents another important milestone for the Company and further solidifies our growing intellectual property portfolio. The potential benefits of this inhaled formulation of RLF-100™ are intriguing and a number of studies to assess its advantages remain ongoing, including a clinical program in Europe as well as the National Institutes of Health (“NIH”)-sponsored ACTIVE-3b/TESICO study and the I-SPY trial sponsored by Quantum Leap,”stated Raghuram (Ram) Selvaraju, Chairman of Relief.
Immune checkpoint inhibitor therapy has emerged as a potential treatment option for a variety of cancers, however immune-related side effects may limit its usage. Pneumonitis develops in as many as 10% to 20% of patients treated with immune checkpoint inhibitors outside of clinical trials, a complication that leads to treatment cessation and immunosuppressive therapy. Furthermore, even after stopping immune checkpoint inhibitors and starting glucocorticoids, many patients develop recurrent pneumonitis, according to current guidelines. On computed CT, broad consolidations are visible, and Quality of Life Questionnaires indicate respiratory problems. Patients with severe lymphocytosis and a low number of regulatory T cells suffer from severe lymphocytosis. As a result, an effective and safe treatment for checkpoint inhibitor-induced pneumonitis is urgently needed.
The striking result that a synthetic form of Vasoactive Intestinal Peptide (aviptadil) administered via inhalation was well tolerated and resulted in alveolar inflammation dampening, radiological and clinical improvement of pneumonitis as a result of checkpoint inhibitor therapy for melanoma was the basis for this issued Patent.
Inhalation is the ideal method of administering aviptadil because it (1) activates swiftly, reducing the risk of unwanted side effects, (2) avoids hepatic first-pass metabolism, and (3) acts locally in the lungs. Because the size diversity among adult lungs is smaller than overall body size variability, inhalation improves dosage dependability. This study was published in the respected New England Journal of Medicine as a Case Report.